APEIRON Biologics AG:製品パイプライン(2014年/製薬企業分析)

◆英語タイトル:APEIRON Biologics AG - Product Pipeline Review - 2014
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC04920CDB
◆発行日:2014年5月30日
◆調査対象地域:グローバル
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥165,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD4,500 ⇒換算¥495,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[APEIRON Biologics AG:製品パイプライン(2014年/製薬企業分析)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

APEIRON Biologics AG – Product Pipeline Review – 2014

Summary

Global Markets Direct’s, ‘APEIRON Biologics AG – Product Pipeline Review – 2014’, provides an overview of the APEIRON Biologics AG’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of APEIRON Biologics AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of APEIRON Biologics AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of APEIRON Biologics AG’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the APEIRON Biologics AG’s pipeline products

Reasons to buy

- Evaluate APEIRON Biologics AG’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of APEIRON Biologics AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the APEIRON Biologics AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of APEIRON Biologics AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of APEIRON Biologics AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of APEIRON Biologics AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
APEIRON Biologics AG Snapshot 5
APEIRON Biologics AG Overview 5
Key Information 5
Key Facts 5
APEIRON Biologics AG – Research and Development Overview 6
Key Therapeutic Areas 6
APEIRON Biologics AG – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Pipeline Products – Out-Licensed Products 10
Out-Licensed Products/Combination Treatment Modalities 11
APEIRON Biologics AG – Pipeline Products Glance 12
APEIRON Biologics AG – Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
APEIRON Biologics AG – Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
APEIRON Biologics AG – Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
APEIRON Biologics AG – Drug Profiles 16
APN-311 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
APN-201 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
APN-301 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
APN-401 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
APN-411 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Drugs for Cancer and Related Conditions 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
APEIRON Biologics AG – Pipeline Analysis 26
APEIRON Biologics AG – Pipeline Products by Target 26
APEIRON Biologics AG – Pipeline Products by Route of Administration 27
APEIRON Biologics AG – Pipeline Products by Molecule Type 28
APEIRON Biologics AG – Pipeline Products by Mechanism of Action 29
APEIRON Biologics AG – Recent Pipeline Updates 30
APEIRON Biologics AG – Dormant Projects 32
APEIRON Biologics AG – Locations And Subsidiaries 33
Head Office 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35

List of Tables
APEIRON Biologics AG, Key Information 5
APEIRON Biologics AG, Key Facts 5
APEIRON Biologics AG - Pipeline by Indication, 2014 7
APEIRON Biologics AG - Pipeline by Stage of Development, 2014 8
APEIRON Biologics AG - Monotherapy Products in Pipeline, 2014 9
APEIRON Biologics AG - Out-Licensed Products in Pipeline, 2014 10
APEIRON Biologics AG - Out-Licensed Products/ Combination Treatment Modalities, 2014 11
APEIRON Biologics AG - Phase III, 2014 12
APEIRON Biologics AG - Phase II, 2014 13
APEIRON Biologics AG - Preclinical, 2014 14
APEIRON Biologics AG - Discovery, 2014 15
APEIRON Biologics AG - Pipeline by Target, 2014 26
APEIRON Biologics AG - Pipeline by Route of Administration, 2014 27
APEIRON Biologics AG - Pipeline by Molecule Type, 2014 28
APEIRON Biologics AG - Pipeline Products by Mechanism of Action, 2014 29
APEIRON Biologics AG - Recent Pipeline Updates, 2014 30
APEIRON Biologics AG - Dormant Developmental Projects,2014 32

List of Figures
APEIRON Biologics AG - Pipeline by Top 10 Indication, 2014 7
APEIRON Biologics AG - Pipeline by Stage of Development, 2014 8
APEIRON Biologics AG - Monotherapy Products in Pipeline, 2014 9
APEIRON Biologics AG - Pipeline by Top 10 Target, 2014 26
APEIRON Biologics AG - Pipeline by Top 10 Route of Administration, 2014 27
APEIRON Biologics AG - Pipeline by Top 10 Molecule Type, 2014 28
APEIRON Biologics AG - Pipeline Products by Top 10 Mechanism of Action, 2014 29

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC04920CDB )"APEIRON Biologics AG:製品パイプライン(2014年/製薬企業分析)" (英文:APEIRON Biologics AG - Product Pipeline Review - 2014)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。